Overview

Upadacitinib for Prurigo Nodularis

Status:
RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Phase:
PHASE4
Details
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Collaborator:
AbbVie
Treatments:
upadacitinib